Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Revlimid opve - jer risiciene, når det anvendes i kombination med dexamethason til behandling af multiple myelomer hos patienter, hos hvem sygdommen tidligere er blevet behandlet mindst 1 gang.
The Committee for Medicinal Products for Human Use (CHMP) decided that, in combination with dexamethasone, Revlimid’ s benefits are greater than its risks for the treatment of multiple myeloma patients who have received at least one prior therapy.